Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Pliant Therapeutics, Inc. PLRX
$22.00
-$0.64 (-2.91%)
На 18:02, 12 мая 2023
+90.91%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
1340484024.00000000
-
week52high
36.64
-
week52low
3.97
-
Revenue
9685000
-
P/E TTM
-9
-
Beta
1.38194600
-
EPS
-3.07000000
-
Last Dividend
0.00000000
-
Next Earnings Date
08 мая 2023 г. в 10:59
Описание компании
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a trials. The company also develops PLN-1474, a small-molecule selective inhibitor of avß1, which completed Phase 1 clinical trial for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition, it is developing two additional preclinical integrin-based programs, which include an oncology program, as well as a program for an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor for treatment of muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | Buy | 09 авг 2022 г. |
| Cantor Fitzgerald | Overweight | Overweight | 26 июл 2022 г. |
| SVB Leerink | Outperform | 20 июл 2022 г. | |
| Cantor Fitzgerald | Overweight | 25 мая 2022 г. | |
| Piper Sandler | Overweight | Overweight | 18 мая 2022 г. |
| Citigroup | Buy | 01 сент 2022 г. | |
| RBC Capital | Outperform | Outperform | 09 ноя 2022 г. |
| Stifel | Buy | 14 дек 2022 г. | |
| JP Morgan | Overweight | 07 дек 2022 г. | |
| SVB Leerink | Outperform | Outperform | 24 янв 2023 г. |
| Citigroup | Buy | Buy | 24 янв 2023 г. |
| Needham | Buy | Buy | 23 янв 2023 г. |
| Cantor Fitzgerald | Overweight | Overweight | 23 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Coulie Bernard | D | 357262 | 15000 | 01 февр 2023 г. |
| Coulie Bernard | D | 240112 | 105 | 01 февр 2023 г. |
| Coulie Bernard | D | 240217 | 5440 | 01 февр 2023 г. |
| Coulie Bernard | D | 245657 | 9455 | 01 февр 2023 г. |
| Coulie Bernard | A | 255112 | 15000 | 01 февр 2023 г. |
| Coulie Bernard | D | 372262 | 4461 | 31 янв 2023 г. |
| Coulie Bernard | D | 146841 | 10539 | 31 янв 2023 г. |
| Coulie Bernard | D | 240112 | 15000 | 31 янв 2023 г. |
| Coulie Bernard | A | 255112 | 4461 | 31 янв 2023 г. |
| Coulie Bernard | A | 250651 | 10539 | 31 янв 2023 г. |
Новостная лента
Why Pliant Therapeutics Stock Is Skyrocketing This Week
The Motley Fool
26 янв 2023 г. в 16:16
The company's experimental idiopathic pulmonary fibrosis drug is showing a lot of promise.
Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
MarketBeat
26 янв 2023 г. в 04:23
Patients with this condition have difficulty breathing due to a buildup of lung scar tissue. They have difficulty breathing due to built-up scar tissue in their lungs.
Pliant Therapeutics (PLRX) Surges 44% in A Week: Here's Why
Zacks Investment Research
25 янв 2023 г. в 12:02
Shares of Pliant Therapeutics (PLRX) have been rising since management reported positive interim data from a mid-stage study evaluating a higher dose of its lead pipeline candidate in IPF patients.
An Unexpected Feat Just Sent Pliant Therapeutics Soaring More Than 50%
Investors Business Daily
23 янв 2023 г. в 10:12
Pliant Therapeutics unveiled promising results for a lung disease treatment on Monday, and PLRX stock rocketed into the stratosphere. The post An Unexpected Feat Just Sent Pliant Therapeutics Soaring More Than 50% appeared first on Investor's Business Daily.
Pliant Therapeutics shares rally 75%
Market Watch
23 янв 2023 г. в 07:49
Shares of Pliant Therapeutics Inc. PLRX, +2.62% soared about 75% in premarket trading on Monday, the day after the company said a high dose of its experimental treatment for idiopathic pulmonary fibrosis met the primary and secondary endpoints in a Phase 2a clinical trial. Pliant, which is testing four different doses of bexotegrast, said 21 patients received the 320 milligram dose — the highest dose — and will continue to receive treatment for 24 weeks.